Tiagabine — Membership Pricing
Tiagabine is not confirmed for no-additional-cost pricing. Membership pricing may be available; confirm the price with the dispensing pharmacy.
Tiagabine Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | Membership pricing may be available |
| Typical Retail | $440.00 |
Membership pricing may be available; confirm the price with the dispensing pharmacy.
About Tiagabine
Tiagabine is a prescription medication. Ask your doctor if Tiagabine is right for you.
How to Check Tiagabine Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Tiagabine at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Other medications in Neurological
What Tiagabine is approved for (FDA label)
Tiagabine HCl is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures.
Source: Read the full FDA label on DailyMed. Label effective date: September 30, 2021.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Tiagabine (FDA label)
The most commonly observed adverse events in placebo-controlled, parallel-group, add-on epilepsy trials associated with the use of tiagabine HCl in combination with other antiepilepsy drugs not seen at an equivalent frequency among placebo-treated patients were dizziness/light-headedness, asthenia/lack of energy, somnolence, nausea, nervousness/irritability, tremor, abdominal pain, and thinking abnormal/difficulty with concentration or attention. Approximately 21% of the 2531 patients who received tiagabine HCl in clinical trials of epilepsy discontinued treatment because of an adverse event. The adverse events most commonly associated with discontinuation were dizziness (1.7%), somnolence (1.6%), depression (1.3%), confusion (1.1%), and asthenia (1.1%).
Source: FDA prescribing information (DailyMed). Set ID: 953ef3cc-e3cb-480f-b9ea-256520fd62b8. SPL document ID: 2a8d7987-54ae-45d7-8224-361dac37e0a4. Label effective date: September 30, 2021. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Tiagabine (FDA label)
Tiagabine HCl is contraindicated in patients who have demonstrated hypersensitivity to the drug or its ingredients.
Source: FDA prescribing information (DailyMed). Set ID: 953ef3cc-e3cb-480f-b9ea-256520fd62b8. SPL document ID: 2a8d7987-54ae-45d7-8224-361dac37e0a4. Label effective date: September 30, 2021. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Tiagabine (FDA label)
In evaluating the potential for interactions among co-administered antiepilepsy drugs (AEDs), whether or not an AED induces or does not induce metabolic enzymes is an important consideration. Carbamazepine, phenytoin, primidone, and phenobarbital are generally classified as enzyme inducers; valproate and gabapentin are not. Tiagabine HCl is considered to be a non-enzyme inducing AED (see PRECAUTIONS, General, Use in Non-Induced Patients ). The drug interaction data described in this section were obtained from studies involving either healthy subjects or patients with epilepsy. Effects of Tiagabine HCl on other Antiepilepsy Drugs (AEDs): Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy. Carbamazepine : Tiagabine had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy. Valproate : Tiagabine causes a slight decrease (about 10%) in steady-state valproate concentrations.
Source: FDA prescribing information (DailyMed). Set ID: 953ef3cc-e3cb-480f-b9ea-256520fd62b8. SPL document ID: 2a8d7987-54ae-45d7-8224-361dac37e0a4. Label effective date: September 30, 2021. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.